Longitudinal study of humoral immune responses in HIV type 1 subtype CRF01_AE (E)-infected Thai patients with different rates of disease progression

AIDS Research and Human Retroviruses

Volumn 19, Issue 4, 2003, Pages 293-305

  Chuenchitra, Thippawan ^a   Polonis, Victoria R ^c   Wasi, Chantapong ^b   Louisirirojchanakul, Suda ^b   Nitayaphan, Sorachai ^a   Sutthent, Ruengpung ^b   Cox, Josephine H ^c   De Souza, Mark S ^a,c   Brown, Arthur E ^a   Birx, Deborah L ^d  

^a ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^d WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; NEUTRALIZING ANTIBODY;

ANTIBODY RESPONSE; ANTIGEN BINDING; ARTICLE; BINDING SITE; CELL LINE; CLADISTICS; CLINICAL ARTICLE; CORRELATION ANALYSIS; CYTOTOXICITY; DISEASE COURSE; DISEASE MARKER; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNOCOMPETENCE; LONGITUDINAL STUDY; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; PRIORITY JOURNAL; SURVIVAL; SYMPTOM; T LYMPHOCYTE; VIRUS ISOLATION; VIRUS LOAD;

ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CD4 LYMPHOCYTE COUNT; CHEMOKINES, CC; DISEASE PROGRESSION; DNA, VIRAL; GENE PRODUCTS, ENV; GENE PRODUCTS, GAG; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; LONGITUDINAL STUDIES; NEUTRALIZATION TESTS; THAILAND; VIRAL LOAD;

EID: 0344490286     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922203764969492     Document Type: Article

References (61)

1. Redfield RR and Burke DS: HIV infection: The clinical picture. Sci Am 1988;259:90-98.
2. Lifson AR, Rutherford GW, and Jaffe HW: The natural history of human immunodeficiency virus infection. J Infect Dis 1998;158:1360-1367.
3. Isaksson B, Albert J, Chiodi F, Furucrona A, Krook A, and Putkonen P: AIDS two months after primary human immunodeficiency virus infection. J Infect Dis 1998;158:866-867.
4. Keet IP, Janssen M, Veugelers PJ, Miedema F, Klein MR, Goudsmit J, Coutinho RA, and de Wolf F: Longitudinal analysis of CD4 T cell counts, T cell reactivity, and human immunodeficiency vires type 1 RNA levels in persons remaining AIDS-free despite CD4 cell counts <200 for >5 years. J Infect Dis 1997;176:665-671.
5. Buchbinder SP, Katz MH, Hessol NA, O'Malley PM, and Holmberg SD: Long-term HIV-1 infection without immunologic progression. AIDS 1994;8:1123-1128.
6. Klein MR and Meidema F: Long-term surivors of HIV-1 infection. Trends Microbiol 1995;3;386-391.
7. Cao Y, Qing L, Zhang L, Safrit J, and Ho DD: Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med 1995;332:201-208.
8. Hogervorst E, Jurriaans S, de Wolf F, Van Wijk A, Wiersma A, Valk M, Roos M, Van Gemen B, Coutinho R, Miedema F, and Goudsmit J: Predictors for non and slow progression in human immunodeficiency virus type 1 infection: Low viral RNA copy numbers in serum and maintenance of high HIV-I p24 specific, but not V3-specific antibody levels. J Infect Dis 1995;171:811-821.
9. + lymphocytes as prognostic markers of HIV-1 infection. J Virol 1997;71:6055-6060.
10. + cell count decline during progression to AIDS correlates with HIV-1 phenotype. AIDS 1992;6:665-669.
11. + cell depletion and progression to AIDS. Ann Intern Med 1993;118:681-688.
12. Allaan JS, Coligan F, Barin J, Sodroski CA, Rosen WA, Haseltine A, Lee TH, and Essex M: Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III. Science 1985;228:1091-1094.
13. Robey WG, Safai B, Oroszlan S, Arthur LO, Gonda MA, Gallo RC, and Fischinger P J: Characterization of envelope and core structural gene products of HTLV-III with sera from AIDS patients. Science 1985;228:593-595.
14. Nixon DF, Broliden K, Ogg G, and Broliden PA: Cellular and humoral antigenic epitopes in HIV and SIV. Immunology 1992;76:519-534.
15. Parren PW, Naniche D, Mondor I, Ditzel HJ, Klassse PJ, Burton DR, and Sattentaau QJ: Neutralization of HIV-1 by gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity. J Virol 1998;72:3512-3519.
16. Cheingsong-Popov R, Panagiotidi C, Bowcock S, Aronstam A, Wadworth J, and Weber J: Relation between humoral responses to HIV Gag and Env proteins at seroconversion and clinical outcome of HIV infection. Br Med J 1991;302:23-26.
17. Binley JM, Klasse PJ, Coa Y, Jones I, Markowitz M, Ho DD, and Moore JP: Differential regulation of the antibody response to Gag and Env proteins of human immunodeficiency virus type 1. J Virol 1997;71:2799-2809.
18. Loomis-Price L, Cox JH, Mascola JR, Vancott TC, Michael NL, Fouts TR, Redfield RR, Robb ML, Wahren B, Sheppard HW, and Birx DL: Correlation between humoral responses to human immunodeficiency virus type 1 envelope and disease progression in early-stage infection. J Infect Dis 1998;178:1306-1316.
19. Wong MT, Warren RQ, Anderson SA, Dolan MJ, Hendrix CW, Blatt SP, Melcher GP, Boswell RN, and Kennedy RC: Longitudinal analysis of the humoral immune response to human immunodeficiency virus type 1 (HIV-1) gp160 epitopes in rapidly progressing and nonprogressing HIV-1 infected subjects. J Infect Dis 1993;168:1523-1527.
20. Zhang YJ, Fracasso C, Fiore JR, Bjorndal A, Angarano G, Gringeri A, and Fenyö EM: Augmented serum neutralizing activity against primary human immunodeficiency virus type 1 (HIV-1) isolates in two groups of HIV-1-infected long-term nonprogressors. J Infect Dis 1997;176:1180-1187.
21. Pilgrim AK, Pantaleo G, Cohen OJ, Fink LM, Zhou JT, Zhou JT, Bolognesi DP, Fauci AS, and Montefiori DC: Neutralizing antibody response to human immunodeficiency virus type 1 in primary infection and long-term nonprogressive infection. J Infect Dis 1997;176:924-932.
22. Montefiori DC, Pantaleo G, Fink LM, Zhou JT, Zhou JY, Bilska M, Miralles GD, and Fauci AS: Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. J Infect Dis 1996;173:60-67.
23. Cecilia D, Kleeberger C, Munoz A, Giorgi JV, and Zolla-Pazner S: A longitudinal study of neutralizing antibodies and disease progression in HIV-1-infected subjects. J Infect Dis 1999;179:1365-1374.
24. Subbarao S, Limpakarnjanaraat K, Mastro TD, Bhumisawasdi J, Warachit P, Jayavasu C, Young NL, Luo CC, Shaffer N, Kalish ML, and Schochetman G: HIV-1 in Thailand, 1994-1995: Persistence of two subtypes with low genetic diversity. AIDS Res Hum Retroviruses 1997;14:319-327.
25. Wasi C, Herring B, Raktham'S, Vanichseni S, Mastro TD, Young NL, Rubsamen-Waigmann H, Von Briesen H, Kalish ML, and Luo CC, Pau CP, Baldwin A, Mullins JI, Delwart EL, Esparza J, Heyward WL, and Osmanov S: Determination of HIV-1 subtypes in injecting drug users in Bangkok, Thailand, using peptide-binding enzyme immunoassay and heteroduplex mobility assay: Evidence of increasing infection with HIV-1 subtype E. AIDS 1995;9:843-849.
26. Limpakarnjanarat K, Ungchusak K, Mastro TD, Young NL, Likhityingvara C, Sangwonloy O, Weniger BG, Pau CP, and Dondero TJ: The epidemiological evolution of HIV-1 subtypes B and E among heterosexuals and injecting drug users in Thailand, 1992-1997. AIDS 1998;12:1108-1109.
27. De Wolf F, Hogervorst ELS, Gouldsmit J, Fenyö EM, Rubsamen-Waigmann H, Holmes H, Galvao-Castro B, Karita E, Wasi C, Sempara SDK, Baan E, Zorgdrager F, Lukashov V, Osmanov S, Kuiken C, Cornelissen M, and WHO Network for HIV Isolation and Characterization: Syncytium-inducing and non-sycytium-inducing capacity of human immunodeficiency virus type 1 subtypes other than B: Phenotype and genotype characteristics. AIDS Res Hum Retroviruses 1994;10:1387-1400.
28. Polonis VR, de Souza MS, Chanbancherd P, Chantakulkij S, Jugsudee A, Loomis-Price LD, Vancott TC, Garner R, Markowitz LE, Brown AE, and Birx DL: HIV type 1 subtype E-infected patients with broadened, dual (B/E) V3 loop serology have increased cross-neutralizing antibodies. AIDS Res Hum Retroviruses 2001;17:69-79.
29. Division of AIDS, National Institute of Allergy and Infectious Diseases: DAIDS Virology Manual for HIV Laboratories. Publication NIH-97-3828. U.S. Department of Health and Human Services, Washington, D.C., 1997.
30. + T cell number and anti-p24 antibody titer in HIV-1 subtype E infections. Thai AIDS J 2000;12:206-211.
31. Louisirirotchanakul S, Beddows S, Cheingsong-Popov R, Shaffer N, Mastro TD, Auewarakul P, Likanonsakul S, Wasi C, and Weber J: Characterization of sera from subjects infected with HIV-1 subtype B and E in Thailand by antibody binding and neutralization. J Acquir Immune Defic Syndr Hum Retrovirol 1998;19:315-320.
32. Louisirirotchanakul S, Beddows S, Cheingsong R, Shaffer N, Mastro TD, Likanonsakul S, Wasi C, Taylor GP, and Weber JN: Role of maternal humoral immunity in vertical transmission of HIV-1 subtype E in Thailand. J Acquit Immune Defic Syndr 1999;21:259-265.
33. Beddows S, Loisirirotchanakul S, Cheingsong-Popov R, Easterbrook PJ, Simmonds P, and Weber J: Neutralization of primary and T-cell line adapted isolates of human immunodeficiency virus type 1: Role of V3-specific antibodies. J Gen Virol 1998;79:77-82.
34. Darden JM, Polonis VR, de Souza MS, Chantakulkij S, Brown AE, Birx DL, and Pattanapanyasat K: A flow cytometric method for measuring neutralization of HIV-1 subtype B and E primary isolates. Cytometry 2000;40:141-150.
35. Sheppard HW, Ascer MS, McRae B, Anderson RE, Lang W, and Allain JP: The initial immune response to HIV and immune system activation determine the outcome HIV disease. J AIDS 1991;4:704-712.
36. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, and Kingsley LA: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996;272:1167-1170.
37. Kanki PJ, Hamel DJ, Sankale JL, Hsieh C, Thior I, Barin F, Woodcock SA, Gueye-Ndiaye A, Zhang E, Montano M, Siby T, Marlink R, N Doye I, Essex ME, and Boup S: Human immunodeficiency virus type 1 subtypes differ in disease progression. J Infect Dis 1999;179:68-73.
38. Marrow JM, Wharton R, Stricker R, and Levy J: Circulating immune complexes in patients with AIDS-associated retrovirus. Clin Immunol Immunopathol 1986;40:515-524.
39. Fenouillet E, Blanes N, Coutellier A, and Gluckmann JC: Relationship between anti-p24 antibody levels and p24 antigenemia in HIV infected patients. AIDS Res Hum Retroviruses 1993;9:1251-1255.
40. Ho DD, McKeating JA, Li XL, Moudgil T, Daar ES, Sun N-C, and Robinson JE: Conformational epitopes on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody. J Virol 1991;65:489-493.
41. Berman PW, Eastman DJ, Wilkes DM, Nakamura GR, Gregory TJ, Schwartz D, Gorse G, Belshe R, Clements ML, and Byrn RA: Comparison of the immune response to recombinant gp120 in humans and chimpanzees. AIDS 1994:8:591-601.
42. Delwart EL, Pan H, Sheppard HW, Wolpert D, Neumann AU, Korber B, and Mullins JI: Slower evolution of human immunodeficiency virus type 1 quasispecies during progression to AIDS. J Virol 1997;71:7498-7508.
43. + T-cell counts and T-cell function in long-term AIDS-free infection. AIDS 1998;12:1591-1600.
44. Vancott TC, Polonis VR, Loomis LD, Michael NL, Nara PL, and Birx DL: Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1. AIDS Res Hum Retroviruses 1995;11:1379-1391.
45. Burton DR and Montefiori DC: The anibody response in HIV-1 infection. AIDS 1997;11(Suppl. A):S87-S98.
46. Stamatatos L and Cheng-Mayer C: Structural modulations of the envelope gp120 glycoprotein of human immunodeficiency virus type 1 upon oligomerization and differential V3 loop epitope exposure of isolates displaying distinct tropism upon virion-soluble receptor binding. J Virol 1995;69:6191-6198.
47. Sullivan NY, Sun Y, Hofmann J Li, Hofmann W, and Sodroski J: Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line passaged human immunodeficiency virus type 1 isolates. J Virol 1995;69:4413-4422.
48. Moore JP and Ho DD: HIV-1 neutralization the consequences of viral adaptation to growth on transformed T cells. AIDS 1995;9(Suppl. A):S117-S136.
49. York J, Follis KE, Trahey M, Nyambi PN, Zolla-Pazner S, and Nunberg JH: Antibody binding and neutralization of primary and T-cell line-adapted isolates of human immunodeficiency virus type 1. J Virol 2001;75:2741-2752.
50. + lymphocyte counts: Immunologic and virologic characteristics. J Infect Dis 1991;163:959-965.
51. Dalgleish A, Sinclair A, Stell M, Beatson D, Ludlam C, and Habeshaw J: Failure of ADCC to predict HIV-associated disease progression or outcome in a haemophiliac cohort. Clin Exp Immunol 1990;81:5-10.
52. Rook AH, Lane HC, Folks T, McCoy S, Alter H, and Fauci AS: Sera from HTLV-III/LAV antibody-positive individuals mediate antibody-dependent cellular cytotoxicity against HTLV-III/LAV-infected T cells. J Immunol 1987;138:1064-1067.
53. Baum LL, Cassutt KJ, Knigge K, Khattri R, Margolick J, Rinaldo C, Kleeberger CA, Nishanian P, Henrard DR, and Phair J: HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression. J Immunol 1996;157:2168-2173.
54. Ljunggren K, Moschese V, Broliden PA, Giaquinto C, Quinti I, Fenyö EM, Wahren B, Rossi P, and Jondal M: Antibodies mediating cellular cytotoxicity and neutralization correlate with a better clinical stage in children born to human immunodeficiency virus-infected mothers. J Infect Dis 1990;161:198-202.
55. Broliden K, Moschese V, Tovo PA, Moschese V, Scarlatti G, Broliden PA, Fundaro C, and Rossi P: Antibody-dependent cellular cytotoxicity and neutralizing activity in sera of HIV-1-infected mothers and their children. Clin Exp Immunol 1993;93:56-64.
56. Kalish ML, Baldwin A, Raktham S, Wasi C, Luo CC, Schochetman G, Mastro TD, Young N, Vanichseni S, and Rubsamen-Waigmann H: The evolving molecular epidemiology of HIV-1 envelope subtypes in injecting drug users in Bangkok, Thailand: Implications for HIV vaccine trials. AIDS 1995;9:851-857.
57. Modrow S, Hahn BH, Shaw GM, Gallo RC, Wong-Staal F, and Wolf H: Computer-assisted analysis of envelope protein sequences of seven human immunodeficiency virus isolates: Prediction of antigenic epitopes in conserved and variable regions. J Virol 1987;61:570-578.
58. Alsmadi O and Tilley SA: Antibody-dependent cellular cytotoxicity directed against cells expressing human immunodeficiency virus type 1 envelope of primary or laboratory-adapted strains by human and chimpanzee monoclonal antibodies of different epitope specificities. J Virol 1998;72:286-293.
59. Weinhold KJ, Lyerly HK, Mathews TJ, Tyler DS, Ahearne PM, Stine KC, Langlois AJ, Durack DT, and Bolognesi DP: Cellular anti-gp120 cytolytic reactivities in HIV-1 seropositive individuals. Lancet 1988;1:902-905.
60. 3. Scand J Immunol 1997;45:103-111.
61. DeSouza MS, Karnasuta C, Brown AE, Markowitz LE, Nitayaphan S, Garner RP, McNeil JG, Birx DL, and Cox JH: A comparative study of the impact of HIV infection on natural killer cell number and function in Thais and North Americans. AIDS Res Hum Retroviruses 2000;16:1061-1066.